• 1

    SiegelRWardEBrawleyOJemalA. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin2011;61:212236.

    • Search Google Scholar
    • Export Citation
  • 2

    ChengLEngCNiemanLZ. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncolin press.

    • Search Google Scholar
    • Export Citation
  • 3

    EdgeSBByrdDRComptonCC eds. AJCC Cancer Staging Manual7th ed.New York, NY: Springer; 2010.

  • 4

    HemminkiKEngC. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet2004;41:801807.

    • Search Google Scholar
    • Export Citation
  • 5

    HemminkiKChenB. Familial risk for colorectal cancers are mainly due to heritable causes. Cancer Epidemiol Biomarkers Prev2004;13:12531256.

    • Search Google Scholar
    • Export Citation
  • 6

    AhsanHNeugutAIGarbowskiGC. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med1998;128:900905.

    • Search Google Scholar
    • Export Citation
  • 7

    BonelliLMartinesHConioM. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer1988;41:513517.

    • Search Google Scholar
    • Export Citation
  • 8

    HampelHFrankelWLMartinE. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol2008;26:57835788.

    • Search Google Scholar
    • Export Citation
  • 9

    LynchHTde la ChapelleA. Hereditary colorectal cancer. N Engl J Med2003;348:919932.

  • 10

    GaliatsatosPFoulkesWD. Familial adenomatous polyposis. Am J Gastroenterol2006;101:385398.

  • 11

    AaltonenLASalovaaraRKristoP. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med1998;338:14811487.

    • Search Google Scholar
    • Export Citation
  • 12

    HampelHFrankelWLMartinE. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med2005;352:18511860.

    • Search Google Scholar
    • Export Citation
  • 13

    HendriksYMde JongAEMorreauH. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin2006;56:213225.

    • Search Google Scholar
    • Export Citation
  • 14

    WrightDMArnoldJLParryB. Immunohistochemistry to detect hereditary nonpolyposis colorectal cancer in young patients: the 7-year Auckland experience. Dis Colon Rectum2011;54:552558.

    • Search Google Scholar
    • Export Citation
  • 15

    Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med2009;11:3541.

    • Search Google Scholar
    • Export Citation
  • 16

    ComptonCCGreeneFL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin2004;54:295308.

  • 17

    JessupJMGundersonLLGreeneFL. 2010 staging system for colon and rectal carcinoma. Ann Surg Oncol2011;18:15131517.

  • 18

    GundersonLLJessupJMSargentDJ. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol2010;28:256263.

    • Search Google Scholar
    • Export Citation
  • 19

    GundersonLLJessupJMSargentDJ. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol2010;28:264271.

    • Search Google Scholar
    • Export Citation
  • 20

    ComptonCC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med2000;124:10161025.

    • Search Google Scholar
    • Export Citation
  • 21

    ComptonCCFieldingLPBurgartLJ. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med2000;124:979994.

    • Search Google Scholar
    • Export Citation
  • 22

    NissanAStojadinovicAShiaJ. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol2006;24:40784084.

    • Search Google Scholar
    • Export Citation
  • 23

    WashingtonMKBerlinJBrantonP. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med2009;133:15391551.

    • Search Google Scholar
    • Export Citation
  • 24

    FujitaSShimodaTYoshimuraK. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol2003;84:127131.

    • Search Google Scholar
    • Export Citation
  • 25

    LiebigCAyalaGWilksJ. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol2009;27:51315137.

  • 26

    QuahHMChouJFGonenM. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum2008;51:503507.

    • Search Google Scholar
    • Export Citation
  • 27

    LoDSPollettASiuLL. Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer. Cancer2008;112:5054.

    • Search Google Scholar
    • Export Citation
  • 28

    UenoHMochizukiHHashiguchiY. Extramural cancer deposits without nodal structure in colorectal cancer: optimal categorization for prognostic staging. Am J Clin Pathol2007;127:287294.

    • Search Google Scholar
    • Export Citation
  • 29

    BirbeckKFMacklinCPTiffinNJ. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg2002;235:449457.

    • Search Google Scholar
    • Export Citation
  • 30

    GoldsteinNSTurnerJR. Pericolonic tumor deposits in patients with T3N+MO colon adenocarcinomas: markers of reduced disease free survival and intra-abdominal metastases and their implications for TNM classification. Cancer2000;88:22282238.

    • Search Google Scholar
    • Export Citation
  • 31

    PuppaGMaisonneuvePSonzogniA. Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. Mod Pathol2007;20:843855.

    • Search Google Scholar
    • Export Citation
  • 32

    UenoHMochizukiH. Clinical significance of extrabowel skipped cancer infiltration in rectal cancer. Surg Today1997;27:617622.

  • 33

    Le VoyerTESigurdsonERHanlonAL. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol2003;21:29122919.

    • Search Google Scholar
    • Export Citation
  • 34

    BilimoriaKYPalisBStewartAK. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum2008;51:154161.

  • 35

    SarliLBaderGIuscoD. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer2005;41:272279.

  • 36

    WongSLJiHHollenbeckBK. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA2007;298:21492154.

  • 37

    GonenMSchragDWeiserMR. Nodal staging score: a tool to assess adequate staging of node-negative colon cancer. J Clin Oncol2009;27:61666171.

    • Search Google Scholar
    • Export Citation
  • 38

    RedstonMComptonCCMiedemaBW. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol2006;24:878883.

    • Search Google Scholar
    • Export Citation
  • 39

    BertagnolliMMiedemaBRedstonM. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg2004;240:624628.

    • Search Google Scholar
    • Export Citation
  • 40

    NouraSYamamotoHMiyakeY. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res2002;8:759767.

    • Search Google Scholar
    • Export Citation
  • 41

    SahaSDanAGBeutlerT. Sentinel lymph node mapping technique in colon cancer. Semin Oncol2004;31:374381.

  • 42

    TurnerRRNoraDTTrochaSDBilchikAJ. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch Pathol Lab Med2003;127:673679.

    • Search Google Scholar
    • Export Citation
  • 43

    WieseDASahaSBadinJ. Pathologic evaluation of sentinel lymph nodes in colorectal carcinoma. Arch Pathol Lab Med2000;124:17591763.

  • 44

    WoodTFNoraDTMortonDL. One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: detection of missed micrometastases. J Gastrointest Surg2002;6:322329; discussion 229–330.

    • Search Google Scholar
    • Export Citation
  • 45

    JassJRO’BrienMJRiddellRHSnoverDC. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Hum Pathol2007;38:537545.

    • Search Google Scholar
    • Export Citation
  • 46

    NouraSYamamotoHOhnishiT. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol2002;20:42324241.

    • Search Google Scholar
    • Export Citation
  • 47

    YasudaKAdachiYShiraishiN. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol2001;8:300304.

    • Search Google Scholar
    • Export Citation
  • 48

    GorhamEDGarlandCFGarlandFC. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med2007;32:210216.

    • Search Google Scholar
    • Export Citation
  • 49

    LappeJMTravers-GustafsonDDaviesKM. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr2007;85:15861591.

    • Search Google Scholar
    • Export Citation
  • 50

    NgKMeyerhardtJAWuK. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol2008;26:29842991.

    • Search Google Scholar
    • Export Citation
  • 51

    NgKSargentDJGoldbergRM. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol2011;29:15991606.

    • Search Google Scholar
    • Export Citation
  • 52

    Dietary reference intakes for calcium and vitamin D. Institute of Medicine of the National Academies; 2010. Available at: http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx. Accessed August 24 2011.

    • Search Google Scholar
    • Export Citation
  • 53

    CooperHSDeppischLMGourleyWK. Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology1995;108:16571665.

    • Search Google Scholar
    • Export Citation
  • 54

    MarkowitzAJWinawerSJ. Management of colorectal polyps. CA Cancer J Clin1997;47:93112.

  • 55

    CooperHS. Surgical pathology of endoscopically removed malignant polyps of the colon and rectum. Am J Surg Pathol1983;7:613623.

  • 56

    CooperHS. Pathologic issues in the treatment of endoscopically removed malignant colorectal polyps. J Natl Compr Canc Netw2007;5:991996.

    • Search Google Scholar
    • Export Citation
  • 57

    HassanCZulloARisioM. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis. Dis Colon Rectum2005;48:15881596.

    • Search Google Scholar
    • Export Citation
  • 58

    CranleyJPPetrasRECareyWD. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma?Gastroenterology1986;91:419427.

    • Search Google Scholar
    • Export Citation
  • 59

    HaggittRCGlotzbachRESofferEEWrubleLD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology1985;89:328336.

    • Search Google Scholar
    • Export Citation
  • 60

    OtaDMNelsonHWeeksJC. Controversies regarding laparoscopic colectomy for malignant diseases. Curr Opin Gen Surg1994:208213.

  • 61

    SeitzUBohnackerSSeewaldS. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum2004;47:17891796.

    • Search Google Scholar
    • Export Citation
  • 62

    UenoHMochizukiHHashiguchiY. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology2004;127:385394.

    • Search Google Scholar
    • Export Citation
  • 63

    VolkEEGoldblumJRPetrasRE. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology1995;109:18011807.

    • Search Google Scholar
    • Export Citation
  • 64

    WinawerSJFletcherRHMillerL. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology1997;112:594642.

  • 65

    BalthazarEJMegibowAJHulnickDNaidichDP. Carcinoma of the colon: detection and preoperative staging by CT. AJR Am J Roentgenol1988;150:301306.

    • Search Google Scholar
    • Export Citation
  • 66

    CohenAM. Surgical considerations in patients with cancer of the colon and rectum. Semin Oncol1991;18:381387.

  • 67

    WestNPHohenbergerWWeberK. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol2010;28:272278.

    • Search Google Scholar
    • Export Citation
  • 68

    BergerACSigurdsonERLeVoyerT. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol2005;23:87068712.

    • Search Google Scholar
    • Export Citation
  • 69

    LacyAMGarcia-ValdecasasJCDelgadoS. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet2002;359:22242229.

    • Search Google Scholar
    • Export Citation
  • 70

    BuunenMVeldkampRHopWC. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol2009;10:4452.

    • Search Google Scholar
    • Export Citation
  • 71

    JayneDGGuillouPJThorpeH. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol2007;25:30613068.

    • Search Google Scholar
    • Export Citation
  • 72

    Laparoscopically assisted colectomy is as safe and effective as open colectomy in people with colon cancer Abstracted from: NelsonHSargentDWieandHS; for the Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med2004; 350: 20502059. Cancer Treat Rev 2004;30:707–709.

    • Search Google Scholar
    • Export Citation
  • 73

    FleshmanJSargentDJGreenE. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg2007;246:655662.

    • Search Google Scholar
    • Export Citation
  • 74

    BonjerHJHopWCNelsonH. Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg2007;142:298303.

  • 75

    JacksonTDKaplanGGArenaG. Laparoscopic versus open resection for colorectal cancer: a metaanalysis of oncologic outcomes. J Am Coll Surg2007;204:439446.

    • Search Google Scholar
    • Export Citation
  • 76

    KuhryESchwenkWGaupsetR. Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials. Cancer Treat Rev2008;34:498504.

    • Search Google Scholar
    • Export Citation
  • 77

    KuhryEBonjerHJHaglindE. Impact of hospital case volume on short-term outcome after laparoscopic operation for colonic cancer. Surg Endosc2005;19:687692.

    • Search Google Scholar
    • Export Citation
  • 78

    KienlePWeitzJKochMBuchlerMW. Laparoscopic surgery for colorectal cancer. Colorectal Dis2006;8Suppl 3:3336.

  • 79

    WagmanLD. Laparoscopic and open surgery for colorectal cancer: reaching equipoise?J Clin Oncol2007;25:29962998.

  • 80

    NelsonHWeeksJCWieandHS. Proposed phase III trial comparing laparoscopic-assisted colectomy versus open colectomy for colon cancer. J Natl Cancer Inst Monogr1995:5156.

    • Search Google Scholar
    • Export Citation
  • 81

    WishnerJDBakerJWHoffmanGC. Laparoscopic-assisted colectomy. The learning curve. Surg Endosc1995;9:11791183.

  • 82

    SaltzLB. Adjuvant therapy for colon cancer. Surg Oncol Clin N Am2010;19:819827.

  • 83

    AndreTBoniCMounedji-BoudiafL. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med2004;350:23432351.

    • Search Google Scholar
    • Export Citation
  • 84

    de GramontABoniCNavarroM. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 3501.

    • Search Google Scholar
    • Export Citation
  • 85

    AndreTBoniCNavarroM. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol2009;27:31093116.

    • Search Google Scholar
    • Export Citation
  • 86

    de GramontABoniCNavarroM. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4007.

    • Search Google Scholar
    • Export Citation
  • 87

    BensonABIIISchragDSomerfieldMR. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol2004;22:34083419.

    • Search Google Scholar
    • Export Citation
  • 88

    Des GuetzGUzzanBMorereJF. Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. Cochrane Database Syst Rev2010:CD007046.

    • Search Google Scholar
    • Export Citation
  • 89

    WolmarkNWieandSKueblerJP. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract LBA3500.

    • Search Google Scholar
    • Export Citation
  • 90

    KueblerJPWieandHSO’ConnellMJ. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol2007;25:21982204.

    • Search Google Scholar
    • Export Citation
  • 91

    HallerDGTaberneroJMarounJ. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol2011;29:14651471.

    • Search Google Scholar
    • Export Citation
  • 92

    SchmollHJCartwrightTTaberneroJ. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol2007;25:102109.

    • Search Google Scholar
    • Export Citation
  • 93

    TwelvesCWongANowackiMP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med2005;352:26962704.

  • 94

    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet1995;345:939944.

    • Search Google Scholar
    • Export Citation
  • 95

    AndreTLouvetCMaindrault-GoebelF. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer1999;35:13431347.

    • Search Google Scholar
    • Export Citation
  • 96

    HallerDGCatalanoPJMacdonaldJS. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol2005;23:86718678.

    • Search Google Scholar
    • Export Citation
  • 97

    WolmarkNRocketteHMamounasE. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol1999;17:35533559.

    • Search Google Scholar
    • Export Citation
  • 98

    SargentDJfor the Adjuvant Colon Cancer Endpoints Group. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: lessons from the 20,800-patient (pt) ACCENT dataset [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4008.

    • Search Google Scholar
    • Export Citation
  • 99

    SargentDJWieandHSHallerDG. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol2005;23:86648670.

    • Search Google Scholar
    • Export Citation
  • 100

    SargentDSobreroAGrotheyA. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol2009;27:872877.

    • Search Google Scholar
    • Export Citation
  • 101

    de GramontAHubbardJShiQ. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol2010;28:460465.

    • Search Google Scholar
    • Export Citation
  • 102

    SargentDShiQYothersG. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer2011;47:990996.

    • Search Google Scholar
    • Export Citation
  • 103

    LoveNBylundCMeropolNJ. How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4020.

    • Search Google Scholar
    • Export Citation
  • 104

    Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol1999;17:13561363.

    • Search Google Scholar
    • Export Citation
  • 105

    GillSLoprinziCLSargentDJ. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?J Clin Oncol2004;22:17971806.

    • Search Google Scholar
    • Export Citation
  • 106

    SchragDRifas-ShimanSSaltzL. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol2002;20:39994005.

    • Search Google Scholar
    • Export Citation
  • 107

    GrayRBarnwellJMcConkeyC. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet2007;370:20202029.

    • Search Google Scholar
    • Export Citation
  • 108

    O’ConnorESGreenblattDYLoconteNK. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol2011;29:33813388.

    • Search Google Scholar
    • Export Citation
  • 109

    MeropolNJ. Ongoing challenge of stage II colon cancer. J Clin Oncol2011;29:33463348.

  • 110

    RibicCMSargentDJMooreMJ. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med2003;349:247257.

    • Search Google Scholar
    • Export Citation
  • 111

    SargentDJMarsoniSMongesG. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol2010;28:32193226.

    • Search Google Scholar
    • Export Citation
  • 112

    MarkowitzSDBertagnolliMM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med2009;361:24492460.

  • 113

    HalvarssonBAndersonHDomanskaK. Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers. Am J Clin Pathol2008;129:238244.

    • Search Google Scholar
    • Export Citation
  • 114

    CunninghamJMChristensenERTesterDJ. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res1998;58:34553460.

    • Search Google Scholar
    • Export Citation
  • 115

    KimGPColangeloLHWieandHS. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol2007;25:767772.

    • Search Google Scholar
    • Export Citation
  • 116

    RothADTejparSDelorenziM. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol2010;28:466474.

    • Search Google Scholar
    • Export Citation
  • 117

    KoopmanMKortmanGAMMekenkampL. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer2009;100:266273.

    • Search Google Scholar
    • Export Citation
  • 118

    TejparSBosmanFDelorenziM. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4001.

    • Search Google Scholar
    • Export Citation
  • 119

    HutchinsGSouthwardKHandleyK. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol2011;29:12611270.

    • Search Google Scholar
    • Export Citation
  • 120

    KerrDJMidgleyR. Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?J Clin Oncol2010;28:32103212.

  • 121

    NgKSchragD. Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch?J Clin Oncol2010;28:32073210.

  • 122

    BiagiJJRaphaelMJMackillopWJ. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA2011;305:23352342.

    • Search Google Scholar
    • Export Citation
  • 123

    Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet2000;355:15881596.

    • Search Google Scholar
    • Export Citation
  • 124

    JagerEHeikeMBernhardH. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol1996;14:22742279.

    • Search Google Scholar
    • Export Citation
  • 125

    O’ConnellMJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer1989;63:10261030.

    • Search Google Scholar
    • Export Citation
  • 126

    YothersGAO’ConnellMJColangeloL. 5-FU and leucovorin (Lv) with or without oxaliplatin (Ox) for adjuvant treatment of stage II and III colon cancer: long-term follow-up of NSABP C-07 with survival analysis. Presented at the 2010 Gastrointestinal Cancers Symposium; January 22–24, 2010; Orlando, Florida. Abstract 401.

    • Search Google Scholar
    • Export Citation
  • 127

    de GramontACutsemEVTaberneroJ. AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer [abstract]. J Clin Oncol2011;29(Suppl 4):Abtract 362.

    • Search Google Scholar
    • Export Citation
  • 128

    SaltzLBNiedzwieckiDHollisD. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol2007;25:34563461.

    • Search Google Scholar
    • Export Citation
  • 129

    RothenbergMLMeropolNJPoplinEA. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol2001;19:38013807.

    • Search Google Scholar
    • Export Citation
  • 130

    PapadimitriouCAPapakostasPKarinaM. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med2011;9:10.

    • Search Google Scholar
    • Export Citation
  • 131

    Van CutsemELabiancaRBodokyG. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol2009;27:31173125.

    • Search Google Scholar
    • Export Citation
  • 132

    YchouMRaoulJLDouillardJY. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol2009;20:674680.

    • Search Google Scholar
    • Export Citation
  • 133

    AllegraCJYothersGO’ConnellMJ. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol2011;29:1116.

    • Search Google Scholar
    • Export Citation
  • 134

    AlbertsSRSargentDJSmyrkTC. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147 [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract CRA3507.

    • Search Google Scholar
    • Export Citation
  • 135

    GoldbergRMSargentDJThibodeauSN. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147 [abstract]. J Clin Oncol2010;28 (Suppl 1):Abstract 3508.

    • Search Google Scholar
    • Export Citation
  • 136

    Cantero-MunozPUrienMARuano-RavinaA. Efficacy and safety of intraoperative radiotherapy in colorectal cancer: a systematic review. Cancer Lett2011;306:121133.

    • Search Google Scholar
    • Export Citation
  • 137

    HongTSRitterMATomeWAHarariPM. Intensity-modulated radiation therapy: emerging cancer treatment technology. Br J Cancer2005;92:18191824.

    • Search Google Scholar
    • Export Citation
  • 138

    LeeWSYunSHChunHK. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis2007;22:699704.

    • Search Google Scholar
    • Export Citation
  • 139

    Van CutsemENordlingerBAdamR. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer2006;42:22122221.

    • Search Google Scholar
    • Export Citation
  • 140

    YooPSLopez-SolerRILongoWEChaCH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer2006;6:202207.

    • Search Google Scholar
    • Export Citation
  • 141

    AlbertsSRHorvathWLSternfeldWC. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol2005;23:92439249.

    • Search Google Scholar
    • Export Citation
  • 142

    KemenyN. Management of liver metastases from colorectal cancer. Oncology (Williston Park)2006;20:116111761179; discussion 1179–1180 1185–1186.

    • Search Google Scholar
    • Export Citation
  • 143

    MuratoreAZorziDBouzariH. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?Ann Surg Oncol2007;14:766770.

    • Search Google Scholar
    • Export Citation
  • 144

    FongYCohenAMFortnerJG. Liver resection for colorectal metastases. J Clin Oncol1997;15:938946.

  • 145

    HayashiMInoueYKomedaK. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg2010;10:27.

    • Search Google Scholar
    • Export Citation
  • 146

    TsaiMSSuYHHoMC. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol2007;14:786794.

    • Search Google Scholar
    • Export Citation
  • 147

    FosterJH. Treatment of metastatic disease of the liver: a skeptic’s view. Semin Liver Dis1984;4:170179.

  • 148

    StanglRAltendorf-HofmannACharnleyRMScheeleJ. Factors influencing the natural history of colorectal liver metastases. Lancet1994;343:14051410.

    • Search Google Scholar
    • Export Citation
  • 149

    AdamRDelvartVPascalG. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg2004;240:644657; discussion 657–658.

    • Search Google Scholar
    • Export Citation
  • 150

    ChotiMASitzmannJVTiburiMF. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg2002;235:759766.

    • Search Google Scholar
    • Export Citation
  • 151

    EliasDLiberaleGVernereyD. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol2005;12:900909.

    • Search Google Scholar
    • Export Citation
  • 152

    FongYSaloJ. Surgical therapy of hepatic colorectal metastasis. Semin Oncol1999;26:514523.

  • 153

    PawlikTMScogginsCRZorziD. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg2005;241:715722.

    • Search Google Scholar
    • Export Citation
  • 154

    VenookAP. The Kemeny article reviewed: management of liver metastases from colorectal cancer: review 2. Available at: http://www.cancernetwork.com/display/article/10165/108033. Accessed September 30 2011.

    • Search Google Scholar
    • Export Citation
  • 155

    CharnsangavejCClaryBFongY. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:12611268.

    • Search Google Scholar
    • Export Citation
  • 156

    PoultsidesGAServaisELSaltzLB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol2009;27:33793384.

    • Search Google Scholar
    • Export Citation
  • 157

    CarpizoDRAreCJarnaginW. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol2009;16:21382146.

    • Search Google Scholar
    • Export Citation
  • 158

    CarpizoDRD’AngelicaM. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Ann Surg Oncol2009;16:24112421.

    • Search Google Scholar
    • Export Citation
  • 159

    PulitanoCBodingbauerMAldrighettiL. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol2011;18:13801388.

    • Search Google Scholar
    • Export Citation
  • 160

    de JongMCMayoSCPulitanoC. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg2009;13:21412151.

    • Search Google Scholar
    • Export Citation
  • 161

    AdamRBismuthHCastaingD. Repeat hepatectomy for colorectal liver metastases. Ann Surg1997;225:5160; discussion 60–62.

  • 162

    KemenyNHuangYCohenAM. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med1999;341:20392048.

    • Search Google Scholar
    • Export Citation
  • 163

    KemenyNEGonenM. Hepatic arterial infusion after liver resection. N Engl J Med2005;352:734735.

  • 164

    BensonAMulcahyMFSiskinG. Safety, response and survival outcomes of Y90 radioembolization for liver metastases: results from a 151 patient investigational device exemption multi-institutional study [abstract]. J Vasc Interv Radiol2011;22 (Suppl):S3.

    • Search Google Scholar
    • Export Citation
  • 165

    HongKMcBrideJDGeorgiadesCS. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol2009;20:360367.

    • Search Google Scholar
    • Export Citation
  • 166

    LimLGibbsPYipD. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer2005;5:132.

    • Search Google Scholar
    • Export Citation
  • 167

    MulcahyMFLewandowskiRJIbrahimSM. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer2009;115:18491858.

    • Search Google Scholar
    • Export Citation
  • 168

    van HazelGAPavlakisNGoldsteinD. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol2009;27:40894095.

    • Search Google Scholar
    • Export Citation
  • 169

    KatzAWCarey-SampsonMMuhsAG. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys2007;67:793798.

    • Search Google Scholar
    • Export Citation
  • 170

    HendliszAVan den EyndeMPeetersM. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol2010;28:36873694.

    • Search Google Scholar
    • Export Citation
  • 171

    TownsendAPriceTKarapetisC. Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database Syst Rev2009:CD007045.

    • Search Google Scholar
    • Export Citation
  • 172

    ACR–ASTRO Practice Guideline for Intensity-Modulated Radiation Therapy (IMRT). The American College of Radiology. Available at: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/ro/imrt.aspx. Accessed August 24 2011.

    • Search Google Scholar
    • Export Citation
  • 173

    ChangDTSwaminathAKozakM. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer2011;117:40604069.

    • Search Google Scholar
    • Export Citation
  • 174

    MeyerJCzitoBYinFFWillettC. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. Clin Colorectal Cancer2007;6:348356.

    • Search Google Scholar
    • Export Citation
  • 175

    TopkanEOnalHCYavuzMN. Managing liver metastases with conformal radiation therapy. J Support Oncol2008;6:91315.

  • 176

    AbdallaEKVautheyJ-NEllisLM. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg2004;239:818825.

    • Search Google Scholar
    • Export Citation
  • 177

    de JongMCPulitanoCRiberoD. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg2009;250:440448.

    • Search Google Scholar
    • Export Citation
  • 178

    GleisnerALChotiMAAssumpcaoL. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg2008;143:12041212.

    • Search Google Scholar
    • Export Citation
  • 179

    HurHKoYTMinBS. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg2009;197:728736.

    • Search Google Scholar
    • Export Citation
  • 180

    ReuterNPWoodallCEScogginsCR. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent?J Gastrointest Surg2009;13:486491.

    • Search Google Scholar
    • Export Citation
  • 181

    AbdallaEK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg2009;197:737739.

    • Search Google Scholar
    • Export Citation
  • 182

    WongSLManguPBChotiMA. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol2010;28:493508.

    • Search Google Scholar
    • Export Citation
  • 183

    Altendorf-HofmannAScheeleJ. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am2003;12:165192.

    • Search Google Scholar
    • Export Citation
  • 184

    PawlikTMSchulickRDChotiMA. Expanding criteria for resectability of colorectal liver metastases. Oncologist2008;13:5164.

  • 185

    PozzoCBassoMCassanoA. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol2004;15:933939.

    • Search Google Scholar
    • Export Citation
  • 186

    VautheyJNZorziDPawlikTM. Making unresectable hepatic colorectal metastases resectable--does it work?Semin Oncol2005;32:118122.

  • 187

    FolprechtGGrotheyAAlbertsS. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol2005;16:13111319.

    • Search Google Scholar
    • Export Citation
  • 188

    AdamRAvisarEAricheA. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol2001;8:347353.

    • Search Google Scholar
    • Export Citation
  • 189

    PawlikTMOlinoKGleisnerAL. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg2007;11:860868.

    • Search Google Scholar
    • Export Citation
  • 190

    RivoireMDe CianFMeeusP. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer2002;95:22832292.

    • Search Google Scholar
    • Export Citation
  • 191

    VautheyJ-NPawlikTMRiberoD. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol2006;24:20652072.

    • Search Google Scholar
    • Export Citation
  • 192

    BilchikAJPostonGCurleySA. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol2005;23:90739078.

  • 193

    ChotiMA. Chemotherapy-associated hepatotoxicity: do we need to be concerned?Ann Surg Oncol2009;16:23912394.

  • 194

    KishiYZorziDContrerasCM. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol2010;17:28702876.

    • Search Google Scholar
    • Export Citation
  • 195

    Rubbia-BrandtLAudardVSartorettiP. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol2004;15:460466.

    • Search Google Scholar
    • Export Citation
  • 196

    DelaunoitTAlbertsSRSargentDJ. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol2005;16:425429.

    • Search Google Scholar
    • Export Citation
  • 197

    FolprechtGGruenbergerTBechsteinWO. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol2010;11:3847.

    • Search Google Scholar
    • Export Citation
  • 198

    TanBRZubalBHawkinsW. Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases [abstract]. Presented at the 2009 Gastrointestinal Cancers Symposium 2009; January 15–17, 2009; San Francisco, California. Abstract 497.

    • Search Google Scholar
    • Export Citation
  • 199

    FalconeARicciSBrunettiI. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007;25:16701676.

    • Search Google Scholar
    • Export Citation
  • 200

    SouglakosJAndroulakisNSyrigosK. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer2006;94:798805.

    • Search Google Scholar
    • Export Citation
  • 201

    MasiGVasileELoupakisF. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst2011;103:2130.

    • Search Google Scholar
    • Export Citation
  • 202

    FuchsCSMarshallJMitchellE. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol2007;25:47794786.

    • Search Google Scholar
    • Export Citation
  • 203

    HurwitzHFehrenbacherLNovotnyW. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004;350:23352342.

    • Search Google Scholar
    • Export Citation
  • 204

    SaltzLBClarkeSDiaz-RubioE. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol2008;26:20132019.

    • Search Google Scholar
    • Export Citation
  • 205

    BilchikAJPostonGAdamRChotiMA. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol2008;26:53205321.

    • Search Google Scholar
    • Export Citation
  • 206

    Combination chemotherapy and bevacizumab before or after surgery in treating patients with colorectal cancer with liver metastases that could be removed by surgery. Available at: http://clinicaltrials.gov/ct2/show/NCT01189227?term=NSABP+C-11&rank=1. Accessed August 24 2011.

    • Search Google Scholar
    • Export Citation
  • 207

    LeonardGDBrennerBKemenyNE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol2005;23:20382048.

    • Search Google Scholar
    • Export Citation
  • 208

    van VledderMGde JongMCPawlikTM. Disappearing colorectal liver metastases after chemotherapy: should we be concerned?J Gastrointest Surg2010;14:16911700.

    • Search Google Scholar
    • Export Citation
  • 209

    BenoistSBrouquetAPennaC. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?J Clin Oncol2006;24:39393945.

    • Search Google Scholar
    • Export Citation
  • 210

    AmadoRGWolfMPeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:16261634.

    • Search Google Scholar
    • Export Citation
  • 211

    BartlettDLBerlinJLauwersGY. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:12841292.

    • Search Google Scholar
    • Export Citation
  • 212

    BurokerTRO’ConnellMJWieandHS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol1994;12:1420.

    • Search Google Scholar
    • Export Citation
  • 213

    CassidyJClarkeSDiaz-RubioE. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol2008;26:20062012.

    • Search Google Scholar
    • Export Citation
  • 214

    CheesemanSLJoelSPChesterJD. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer2002;87:393399.

    • Search Google Scholar
    • Export Citation
  • 215

    ColucciGGebbiaVPaolettiG. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol2005;23:48664875.

    • Search Google Scholar
    • Export Citation
  • 216

    CunninghamDHumbletYSienaS. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004;351:337345.

    • Search Google Scholar
    • Export Citation
  • 217

    CunninghamDPyrhonenSJamesRD. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet1998;352:14131418.

    • Search Google Scholar
    • Export Citation
  • 218

    de GramontABossetJFMilanC. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol1997;15:808815.

    • Search Google Scholar
    • Export Citation
  • 219

    de GramontAFigerASeymourM. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000;18:29382947.

    • Search Google Scholar
    • Export Citation
  • 220

    DelaunoitTGoldbergRMSargentDJ. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer2004;101:21702176.

    • Search Google Scholar
    • Export Citation
  • 221

    DouillardJYCunninghamDRothAD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet2000;355:10411047.

    • Search Google Scholar
    • Export Citation
  • 222

    DouillardJYSienaSCassidyJ. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol2010;28:46974705.

    • Search Google Scholar
    • Export Citation
  • 223

    FuchsCSMooreMRHarkerG. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol2003;21:807814.

    • Search Google Scholar
    • Export Citation
  • 224

    GiantonioBJCatalanoPJMeropolNJ. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol2007;25:15391544.

    • Search Google Scholar
    • Export Citation
  • 225

    GoldbergRM. Therapy for metastatic colorectal cancer. Oncologist2006;11:981987.

  • 226

    GoldbergRMRothenbergMLVan CutsemE. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist2007;12:3850.

    • Search Google Scholar
    • Export Citation
  • 227

    GoldbergRMSargentDJMortonRF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol2004;22:2330.

    • Search Google Scholar
    • Export Citation
  • 228

    HallerDGRothenbergMLWongAO. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol2008;26:45444550.

    • Search Google Scholar
    • Export Citation
  • 229

    HurwitzHIFehrenbacherLHainsworthJD. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol2005;23:35023508.

    • Search Google Scholar
    • Export Citation
  • 230

    KabbinavarFFHambletonJMassRD. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol2005;23:37063712.

    • Search Google Scholar
    • Export Citation
  • 231

    KellyHGoldbergRM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol2005;23:45534560.

    • Search Google Scholar
    • Export Citation
  • 232

    KohneCMineurLGreilR. Primary analysis of a phase II study (20060314) combining first-line panitumumab (pmab) with FOLFIRI in the treatment of patients (pts) with metastatic colorectal cancer (mCRC) [abstract]. Presented at the 2010 Gastrointestinal Cancers Symposium; January 22–24, 2010; Orlando, Florida. Abstract 414.

    • Search Google Scholar
    • Export Citation
  • 233

    Maindrault-GoebelFLouvetCAndreT. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer1999;35:13381342.

    • Search Google Scholar
    • Export Citation
  • 234

    PeetersMPriceTJCervantesA. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol2010;28:47064713.

    • Search Google Scholar
    • Export Citation
  • 235

    PetrelliNHerreraLRustumY. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol1987;5:15591565.

    • Search Google Scholar
    • Export Citation
  • 236

    PuntCJTolJRodenburgCJ. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract LBA4011.

    • Search Google Scholar
    • Export Citation
  • 237

    ReidyDLChungKYTimoneyJP. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol2007;25:26912695.

  • 238

    SaltzLClarkeSDiaz-RubioE. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4028.

    • Search Google Scholar
    • Export Citation
  • 239

    Van CutsemE. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist2006;11:10101017.

  • 240

    Van CutsemEHoffPMHarperP. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer2004;90:11901197.

    • Search Google Scholar
    • Export Citation
  • 241

    Van CutsemEKohneCHHitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009;360:14081417.

    • Search Google Scholar
    • Export Citation
  • 242

    Van CutsemEPeetersMSienaS. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol2007;25:16581664.

    • Search Google Scholar
    • Export Citation
  • 243

    Van CutsemETwelvesCCassidyJ. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol2001;19:40974106.

    • Search Google Scholar
    • Export Citation
  • 244

    WolmarkNRocketteHFisherB. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol1993;11:18791887.

    • Search Google Scholar
    • Export Citation
  • 245

    LentzFTranAReyE. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics2005;5:2133.

    • Search Google Scholar
    • Export Citation
  • 246

    O’DwyerPJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist2006;11:992998.

  • 247

    RaymondEFaivreSWoynarowskiJMChaneySG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol1998;25:412.

  • 248

    RothenbergMLBlankeCD. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol1999;26:632639.

  • 249

    TournigandCAndreTAchilleE. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004;22:229237.

    • Search Google Scholar
    • Export Citation
  • 250

    CassidyJTaberneroJTwelvesC. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol2004;22:20842091.

    • Search Google Scholar
    • Export Citation
  • 251

    PorschenRArkenauH-TKubickaS. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol2007;25:42174223.

    • Search Google Scholar
    • Export Citation
  • 252

    FuchsCSMarshallJBarruecoJ. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol2008;26:689690.

    • Search Google Scholar
    • Export Citation
  • 253

    GoldbergRMSargentDJMortonRF. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup trial. J Clin Oncol2006;24:33473353.

    • Search Google Scholar
    • Export Citation
  • 254

    KoopmanMAntoniniNFDoumaJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet2007;370:135142.

    • Search Google Scholar
    • Export Citation
  • 255

    KohneCHDe GreveJHartmannJT. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol2008;19:920926.

    • Search Google Scholar
    • Export Citation
  • 256

    Garcia-AlfonsoPMunoz-MartinAJAlvarez-SuarezS. Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. Br J Cancer2010;103:15241528.

    • Search Google Scholar
    • Export Citation
  • 257

    DucreuxMAdenisAMendiboureJ. Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4086.

    • Search Google Scholar
    • Export Citation
  • 258

    PectasidesDGXanthakisIMakatsorisT. Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG) [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract 3541.

    • Search Google Scholar
    • Export Citation
  • 259

    SargentDJKohneCHSanoffHK. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol2009;27:19481955.

    • Search Google Scholar
    • Export Citation
  • 260

    NordlingerBSorbyeHGlimeliusB. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet2008;371:10071016.

    • Search Google Scholar
    • Export Citation
  • 261

    Eloxatin [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2009.

  • 262

    TournigandCCervantesAFigerA. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol2006;24:394400.

    • Search Google Scholar
    • Export Citation
  • 263

    GamelinLBoisdron-CelleMDelvaR. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res2004;10:40554061.

    • Search Google Scholar
    • Export Citation
  • 264

    GamelinLBoisdron-CelleMMorelA. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol2008;26:11881189; author reply 1189–1190.

    • Search Google Scholar
    • Export Citation
  • 265

    GrotheyANikcevichDASloanJA. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol2011;29:421427.

    • Search Google Scholar
    • Export Citation
  • 266

    HochsterHSGrotheyAChildsBH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol2007;25:40284029.

    • Search Google Scholar
    • Export Citation
  • 267

    KnijnNTolJKoopmanM. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer2010;47:369374.

    • Search Google Scholar
    • Export Citation
  • 268

    KurnialiPCLuoLGWeitbergAB. Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology (Williston Park)2010;24:289292.

    • Search Google Scholar
    • Export Citation
  • 269

    ChibaudelBMaindrault-GoebelFLledoG. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol2009;27:57275733.

    • Search Google Scholar
    • Export Citation
  • 270

    HochsterHSHartLLRamanathanRK. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol2008;26:35233529.

    • Search Google Scholar
    • Export Citation
  • 271

    BokemeyerCBondarenkoIMakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663671.

    • Search Google Scholar
    • Export Citation
  • 272

    Xeloda [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2005.

  • 273

    HallerDGCassidyJClarkeSJ. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol2008;26:21182123.

    • Search Google Scholar
    • Export Citation
  • 274

    SchmollHJArnoldD. Update on capecitabine in colorectal cancer. Oncologist2006;11:10031009.

  • 275

    Camptosar [package insert]. New York, NY: Pfizer, Inc.; 2010.

  • 276

    InnocentiFUndeviaSDIyerL. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol2004;22:13821388.

    • Search Google Scholar
    • Export Citation
  • 277

    UGT1A1 for irinotecan toxicity. LabCorpWeb site. Available at: https://www.labcorp.com. Accessed August 24 2011.

  • 278

    O’DwyerPJCatalanoRB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol2006;24:45344538.

    • Search Google Scholar
    • Export Citation
  • 279

    UGT1A1. Invader ChemistryWeb site. Available at: http://www.invaderchemistry.com/invader_applications/invader-ugt1a1.html. Accessed August 24 2011.

    • Search Google Scholar
    • Export Citation
  • 280

    SobreroAAcklandSClarkeS. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology2009;77:113119.

    • Search Google Scholar
    • Export Citation
  • 281

    Van CutsemELangIFolprechtG. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract 3570.

    • Search Google Scholar
    • Export Citation
  • 282

    MitryEFieldsALBleibergH. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol2008;26:49064911.

    • Search Google Scholar
    • Export Citation
  • 283

    KabbinavarFHurwitzHIFehrenbacherL. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol2003;21:6065.

    • Search Google Scholar
    • Export Citation
  • 284

    KabbinavarFFSchulzJMcCleodM. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol2005;23:36973705.

    • Search Google Scholar
    • Export Citation
  • 285

    SnoerenNVoestEEBergmanAM. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer2010;10:545.

    • Search Google Scholar
    • Export Citation
  • 286

    Avastin [package insert]. South San Francisco, CA: Genentech, Inc.; 2009.

  • 287

    ScappaticciFAFehrenbacherLCartwrightT. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol2005;91:173180.

    • Search Google Scholar
    • Export Citation
  • 288

    CannistraSAMatulonisUAPensonRT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol2007;25:51805186.

    • Search Google Scholar
    • Export Citation
  • 289

    RanpuraVHapaniSWuS. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA2011;305:487494.

  • 290

    HurwitzHISaltzLBVan CutsemE. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol2011;29:17571764.

    • Search Google Scholar
    • Export Citation
  • 291

    GruenbergerBTamandlDSchuellerJ. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol2008;26:18301835.

    • Search Google Scholar
    • Export Citation
  • 292

    ReddySKMorseMAHurwitzHI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg2008;206:96106.

    • Search Google Scholar
    • Export Citation
  • 293

    MilesDHarbeckNEscudierB. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol2011;29:8388.

    • Search Google Scholar
    • Export Citation
  • 294

    MilesDW. Reply to P. Potemski. J Clin Oncol2011;29:e386.

  • 295

    PotemskiP. Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials?J Clin Oncol2011;29:e384385.

    • Search Google Scholar
    • Export Citation
  • 296

    HechtJRMitchellEChidiacT. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009;27:672680.

    • Search Google Scholar
    • Export Citation
  • 297

    TolJKoopmanMCatsA. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med2009;360:563572.

  • 298

    Cetuximab [package insert]. Branchburg, NJ: ImClone Systems Incorporated; 2009.

  • 299

    Vectibix [package insert]. Thousand Oaks, CA: Amgen Inc.; 2009.

  • 300

    BaselgaJRosenN. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol2008;26:15821584.

  • 301

    De RoockWPiessevauxHDe SchutterJ. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008;19:508515.

    • Search Google Scholar
    • Export Citation
  • 302

    KarapetisCSKhambata-FordSJonkerDJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med2008;359:17571765.